Lefamulin

Blog · Antibiotic

Lefamulin

Nature of the antibiotic

Semi-synthetic, pleuromutilin class.
Molecular weight – 567.79 gm/mole

Pleuromutilins

Pleuromutilins (produced by Pleurotus sp.), discovered in the 1950s, have a tricyclic mutilin core.
Tiamulin – the first member of this group, was approved for veterinary use in 1979.
Retapamulin – topical pleuromutilin was approved for human use in 2007.

Mechanism of action

It inhibits protein synthesis by preventing the binding of tRNA for peptide transfer.

It interacts with the A- and P-sites of the peptidyl transferase centre in domain V of the 23s rRNA of the
50S subunit. It interacts by hydrogen bonds, hydrophobic interactions, and Van der Waals forces.

Amino acids attached to the tRNA on P site(' ) is forming a link with the amino acid ( O)attached 
to the tRNA on A site (chain elongation process of the protein synthesis) 
tRNA is leaving 
e site after the 
amino acid(O) 
incorporation in 
the peptide 
chain 
mRNA 
Protein (peptide) 
chain 
E 
P 
Amino 
acid 
Aminoacyl 
-tRNA 
50S ribosomal 
subunit 
30S ribosomal 
subunit 
Once the link between 'and O 
has been established the current A site will become the NEW P site. The tRNA with 'will leave. 
A new tRNA with another amino acid • will attach to the NEW A site

Mechanism of resistance

  • Protection or modification of the ribosomal target: by ABC-F proteins such as vga (A, B, E), lsa(E), sal(A), Cfr methyl transferase,
  • Mutations of ribosomal proteins L3 and L4

There is potential for cross-resistance with chloramphenicol, lincosamides, oxazolidinones, and
streptogramin A.

PK/PD

  • Best PK-PD index – The 24 h free-drug AUC to minimal inhibitory concentration (MIC) ratio.
  • oral bioavailability – 25%
  • Food (esp high fat, high calorie) reduce bioavailability – tablets should be taken 1 hour before or 2 hours after food.
  • Plasma protein binding >/= 95%
  • T1/2 (in patients with community-acquired bacterial pneumonia patients – 8 hours.
  • Lefamulin is primarily metabolized by CYP3A4.
  • Hepatic impairment: IV – dose reduction in severe liver derangement (Child-Pugh C); PO – not recommended in moderate-severe (Child-Pugh B and C).
  • Excretion – mainly in faeces (>705), and urine (approx 15%)

Use

  • FDA approval in 2019 to treat adults with community-acquired bacterial pneumonia (caused by Streptococcus pneumoniae, methicillin-susceptible Staphylococcus aureus, Haemophilus influenzae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumonia).
  • Other potential uses (trial, as per the manufacturer Nabriva) – Acute bacterial skin and skin structure infections (ABSSSI), sexually transmitted infections (STIs), ventilator-associated bacterial pneumonia (VABP), hospital-acquired bacterial pneumonia (HABP), osteomyelitis, and prosthetic joint infections.

Adverse effect

Gastrointestinal adverse effects (diarrhoea, nausea, vomiting), administration site reactions, hepatic enzyme elevation, hypokalemia, insomnia, headache, QT Prolongation.

Caution/contraindication

  • Avoid use in patients with known QT prolongation, ventricular arrhythmias including torsades de pointes, and patients receiving drugs that prolong the QT interval.
  • May cause fetal harm (Females of reproductive age may need effective contraception).
  • C difficile-associated diarrhoea.
  • Avoid in hypersensitivity to lefamulin/Pleuromutilin.
  • Avoid concurrent use with strong or moderate CYP3A inducers or P-gp inducers.
  • Avoid concurrent use of Lefamulin tablets with strong CYP3A inhibitors or P-gp inhibitors.

Spectrum

Gram-positive: Methicillin sensitive Staph aureus (Not MRSA – not evaluated), Streptococcus pneumonia.
Gram-negative: H influenzae
Atypicals: Mycoplasma pneumonia, Chlamydophila pneumonia, Legionella pneumophila.

It is not active against Enterobacteriaceae and Pseudomonas aeruginosa.
The safety and efficacy have not been assessed in the trial for – group A Streptococcus, group B Streptococcus, alpha haemolytic Streptococcus, MRSA.
It is bacteriostatic against MSSA and group A Streptococcus; bacteriocidal against S. pneumoniae, H. influenzae and M. pneumoniae.

Papers/ref:

Disclaimer: This is for academic use only. Managing an infection is complex and depends on taking multiple factors into account. Please speak to your doctor for clinical advice. This article must never be used for clinical purposes.
Scroll to Top